Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7200220 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: RO7200220 Monotherapy | EXPERIMENTAL | Participants with DME received multiple ascending doses of RO7200220 (two doses at the assigned dose level), as intravitreal (IVT) injection, every 6 weeks (Q6W) in multiple cohorts. |
| Part 2: Expansion of RO7200220 Monotherapy | EXPERIMENTAL | Participants with DME who were anti-VEGF and corticosteroid IVT treatment-naive received three doses of RO7200220 monotherapy, as IVT injection, every 4 weeks (Q4W) in Part 2 cohorts. |
| Part 3: RO7200220 in Combination with Ranibizumab | EXPERIMENTAL | Participants with DME received RO7200220 as IVT injection followed by ranibizumab, 0.5 milligrams (mg) as IVT injection in Part 3. |
| Part 4: RO7200220 Monotherapy | EXPERIMENTAL | Participants with UME received multiple doses of RO7200220 (three doses at the assigned dose level), as IVT injection, Q4W in multiple cohorts. |
| Name | Type | Description |
|---|---|---|
| RO7200220 | DRUG | RO7200220 was administered as IVT injection. |
| Ranibizumab | DRUG | Ranibizumab was administered as IVT injection. |
Inclusion Criteria: DME Participants: * Diagnosis of Diabetes Mellitus (DM) (Type 1 or Type 2), as defined by the World Health Organization and/or American Diabetes Association * Macular edema associated with DR defined as macular thickening by spectral domain optical coherence tomography (SD-OCT)...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901, Aflibercept |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Oculis Holding AG | OCS | 2 | PHASE3 | Dexamethasone, Vehicle |
| AbbVie, Inc. | ABBV | 3 | PHASE2 | ABBV-RGX-314 Dose 1, Steroid, Aflibercept |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | bevacizumab |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 IVT, Aflibercept IVT |
| Alvotech | ALVO | 1 | PHASE3 | AVT29, Eylea HD |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
RO7200220 is an investigational small molecule being developed for diabetic macular edema, a condition that causes vision loss due to fluid buildup in the macula. It is also being studied for uveitic macular edema. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
RO7200220 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials of the drug in the United States for diabetic macular edema and uveitic macular edema.
RO7200220 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed, but it remains investigational and has not received FDA approval. The drug is being studied for diabetic macular edema and uveitic macular edema.
RO7200220 has one completed clinical trial, NCT06771271, which investigated the drug as monotherapy and in combination with ranibizumab in participants with diabetic and uveitic macular edema. The study enrolled 85 participants in the United States and was Phase 1.
No, RO7200220 is not the same as ranibizumab. RO7200220 is a small molecule being developed by Roche, while ranibizumab is a separate biologic therapy. In clinical trial NCT06771271, RO7200220 was studied as a monotherapy and in combination with ranibizumab.